181 related articles for article (PubMed ID: 1510426)
1. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.
Lettieri JT; Rogge MC; Kaiser L; Echols RM; Heller AH
Antimicrob Agents Chemother; 1992 May; 36(5):993-6. PubMed ID: 1510426
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily.
Shah A; Lettieri J; Kaiser L; Echols R; Heller AH
J Antimicrob Chemother; 1994 Apr; 33(4):795-801. PubMed ID: 8056698
[TBL] [Abstract][Full Text] [Related]
4. Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses.
Nix DE; Spivey JM; Norman A; Schentag JJ
Ann Pharmacother; 1992 Jan; 26(1):8-10. PubMed ID: 1606348
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers.
Wingender W; Graefe KH; Gau W; Förster D; Beermann D; Schacht P
Eur J Clin Microbiol; 1984 Aug; 3(4):355-9. PubMed ID: 6489326
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of ciprofloxacin: intravenous and increasing oral doses.
Bergan T; Thorsteinsson SB; Solberg R; Bjornskau L; Kolstad IM; Johnsen S
Am J Med; 1987 Apr; 82(4A):97-102. PubMed ID: 3578334
[TBL] [Abstract][Full Text] [Related]
7. Steady-state serum pharmacokinetics and bioequivalence of 500 mg oral versus 200 mg intravenous ciprofloxacin.
Garraffo R; Dellamonica P; Bernard E; Etesse H; Lapalus P
Int J Clin Pharmacol Res; 1989; 9(1):29-35. PubMed ID: 2707923
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects.
Abel S; Russell D; Whitlock LA; Ridgway CE; Nedderman AN; Walker DK
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):60-7. PubMed ID: 18333867
[TBL] [Abstract][Full Text] [Related]
9. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po.
Catchpole C; Andrews JM; Woodcock J; Wise R
J Antimicrob Chemother; 1994 Jan; 33(1):103-10. PubMed ID: 8157550
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Safety, and Tolerability of Single-Dose Intravenous (ZTI-01) and Oral Fosfomycin in Healthy Volunteers.
Wenzler E; Ellis-Grosse EJ; Rodvold KA
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630194
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics of intravenous and oral ciprofloxacin in elderly patients.
Hirata CA; Guay DR; Awni WM; Stein DJ; Peterson PK
Antimicrob Agents Chemother; 1989 Nov; 33(11):1927-31. PubMed ID: 2610503
[TBL] [Abstract][Full Text] [Related]
13. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
Chien SC; Rogge MC; Gisclon LG; Curtin C; Wong F; Natarajan J; Williams RR; Fowler CL; Cheung WK; Chow AT
Antimicrob Agents Chemother; 1997 Oct; 41(10):2256-60. PubMed ID: 9333057
[TBL] [Abstract][Full Text] [Related]
15. Effect of renal function on the bioavailability of ciprofloxacin.
Plaisance KI; Drusano GL; Forrest A; Weir MR; Standiford HC
Antimicrob Agents Chemother; 1990 Jun; 34(6):1031-4. PubMed ID: 2393263
[TBL] [Abstract][Full Text] [Related]
16. Absolute oral bioavailability of ciprofloxacin.
Drusano GL; Standiford HC; Plaisance K; Forrest A; Leslie J; Caldwell J
Antimicrob Agents Chemother; 1986 Sep; 30(3):444-6. PubMed ID: 3777908
[TBL] [Abstract][Full Text] [Related]
17. Effect of famotidine on ciprofloxacin pharmacokinetics after single intravenous and oral doses in rats.
al-Khamis KI; Jim LK; Bawazir SA; Ashour LF; el-Sayed N; el-Sayed YM
J Clin Pharm Ther; 1994 Dec; 19(6):335-9. PubMed ID: 7876363
[TBL] [Abstract][Full Text] [Related]
18. Ciprofloxacin bioavailability is enhanced by oral co-administration with phenazopyridine: a pharmacokinetic study in a Mexican population.
Marcelín-Jiménez G; Angeles AP; Martínez-Rossier L; Fernández S A
Clin Drug Investig; 2006; 26(6):323-8. PubMed ID: 17163266
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of ciprofloxacin in ponies.
Dowling PM; Wilson RC; Tyler JW; Duran SH
J Vet Pharmacol Ther; 1995 Feb; 18(1):7-12. PubMed ID: 7752310
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus).
Kim MS; Lim JH; Park BK; Hwang YH; Yun HI
J Vet Pharmacol Ther; 2006 Oct; 29(5):397-402. PubMed ID: 16958784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
